Crambescidin-816 Acts as a Fungicidal with More Potency than Crambescidin-800 and -830, Inducing Cell Cycle Arrest, Increased Cell Size and Apoptosis in Saccharomyces cerevisiae

Thumbnail Image

Files

2013_marinedrugs_rubiolo_crambescidin.pdf (934.64 KB)
Identifiers
URI: http://hdl.handle.net/10347/23606
E-ISSN: 1660-3397
DOI: 10.3390/md11114419

Publication date

2013

Authors

Advisors

Tutors

Editors

Journal Title

Journal ISSN

Volume Title

Publisher

MDPI
Metrics
Google Scholar
lacobus
Export

Research Projects

Organizational Units

Journal Issue

Abstract

In this paper, we show the effect of crambescidin-816, -800, and -830 on Saccharomyces cerevisiae viability. We determined that, of the three molecules tested, crambescidin-816 was the most potent. Based on this result, we continued by determining the effect of crambescidin-816 on the cell cycle of this yeast. The compound induced cell cycle arrest in G2/M followed by an increase in cell DNA content and size. When the type of cell death was analyzed, we observed that crambescidin-816 induced apoptosis. The antifungal effect indicates that crambescidins, and mostly crambescidin-816, could serve as a lead compound to fight fungal infections

Description

Keywords

Crambescidine-816| Antifungal| Cell cycle arrest| Apoptosis

Bibliographic citation

Rubiolo, J.A.; Ternon, E.; López-Alonso, H.; Thomas, O.P.; Vega, F.V.; Vieytes, M.R.; Botana, L.M. Crambescidin-816 Acts as a Fungicidal with More Potency than Crambescidin-800 and -830, Inducing Cell Cycle Arrest, Increased Cell Size and Apoptosis in Saccharomyces cerevisiae. Mar. Drugs 2013, 11, 4419-4434

Relation

Has part

Has version

Is based on

Is part of

Is referenced by

Is version of

Requires

Sponsors

The research leading to these results has received funding from the following FEDER cofunded-grants: From Ministerio de Ciencia y Tecnología, Spain: AGL2009-13581-CO2-01, AGL2012-40485-CO2-01. From Xunta de Galicia, Spain: 10PXIB261254 PR. From the European Union’s Seventh Framework Programme managed by REA—Research Executive Agency (FP7/2007-2013) under grant agreement Nos. 211326—CP (CONffIDENCE), 265896 BAMMBO, 265409 µAQUA, and 262649 BEADS, 315285 Ciguatools and 312184 PharmaSea. From the Atlantic Area Programme (Interreg IVB Trans-national): 2009-1/117 Pharmatlantic

Rights

© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/)

Collections

Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica
Fisioloxía